Spero Therapeutics Inc (SPRO) stock is down 6.25% over the past week and gets a Bearish rating from InvestorsObserver Sentiment Indicator.
Spero Therapeutics Inc has a Bearish sentiment reading. Find out what this means for you and get the rest of the rankings on SPRO!
What is Stock Sentiment?
Sentiment uses short term technical analysis to gauge whether a stock is desired by investors. As a technical indicator, it focuses on recent trends as opposed to the long term health of the underlying company. Updates for the company such as a earnings release can move the stock away from current trends.
Sentiment is how investors, or the market, feels about a stock. There are lots of ways to measure sentiment. At the core, sentiment is pretty easy to understand. If a stock is going up, investors must be bullish, while if it is going down, sentiment is bearish.
InvestorsObserver’s Sentiment Indicator looks at price trends over the past week and also considers changes in volume. Increasing volume can mean a trend is getting stronger, while decreasing volume can mean a trend is nearing a conclusion.
For stocks that have options, our system also considers the balance between calls, which are often bets that the price will go up, and puts, which are frequently bets that the price will fall.
What's Happening With SPRO Stock Today?
Spero Therapeutics Inc (SPRO) stock is lower by -3.51% while the S&P 500 has risen 2.02% as of 4:00 PM on Tuesday, May 17. SPRO is down -$0.06 from the previous closing price of $1.71 on volume of 530,193 shares. Over the past year the S&P 500 is down -1.79% while SPRO is down -87.69%. SPRO lost -$2.91 per share in the over the last 12 months.
More About Spero Therapeutics Inc
Spero Therapeutics Inc is a clinical-stage biopharmaceutical firm. It focuses on identifying, developing and commercializing novel treatments for MDR (Multi-drug-resistant) bacterial infections and rare diseases. The company's product candidate, tebipenem pivoxil hydrobromide or tebipenem HBr, is designed to be an oral carbapenem-class antibiotic for use in adults to treat MDR Gram-negative infections. It is also developing SPR720, a novel oral antibiotic designed for the treatment of a rare, orphan disease caused by pulmonary non-tuberculous mycobacterial infections, or NTM disease. Besides, it is also focused on SPR206, a next-generation polymyxin investigational product candidate, being developed as an IV-administered medicine to treat MDR Gram-negative infections in the hospital.
Click Here to get the full Stock Report for Spero Therapeutics Inc stock.